Stenting of femoropopliteal lesions using interwoven nitinol stents

Abstract

Our midterm results show that Supera stents are durable in treating femoropopliteal lesions, with notably high patency rates in patients with long lesion lengths.

Short-term Results of the RAPID Randomized Trial of the Legflow Paclitaxel-Eluting Balloon With Supera Stenting vs Supera Stenting Alone for the Treatment of Intermediate and Long Superficial Femoral Artery Lesions

“…15,19 Remarkably and unexpectedly, the efficacy data do not match with other studies using DCBs + primary stenting 24 or with Supera studies. [25][26][27]29,30,36 This holds for both groups and also in the intention-to-treat as well as the per-protocol analyses. Angiograms in patients with ISR were analyzed with a special focus on stent configuration (nominal, lengthening, or shortening), but it offered no explanation for the relatively low primary patency rates.…”

“…The use of antirestenotic technology, either DCBs or drug-eluting stents (DES), has proven its ability to inhibit neointimal hyperplasia and its efficacy in reducing restenosis in the SFA. [13][14][15]17,19,24 Results have shown a clear benefit of standard nitinol stents and DES over BA in both short and long lesions of the SFA, [7][8][9]11,17,23,[25][26][27][28][29][30] but these studies included only a low percentage of occluded lesions (25%-53%).…”

“…29 However, current data on performance of the Supera stent in intermediate and long complex SFA lesions have proven to be excellent. [25][26][27]30,36 The main difference between regular nitinol stents and the Supera stent is the lack of chronic outward force, which is assumed to be the most important contributor to ISR. For this reason, it is questionable whether DCB support can further improve these patency rates.…”

Adjunctive stent use during endovascular intervention to the femoropopliteal artery with drug coated balloons: Insights from the XLPAD registry

“…16,[20][21][22][23] Interwoven nitinol stents, due to their high radial force and flexibility, have also helped to overcome many of the disadvantages associated with selfexpanding bare-metal nitinol stents. [24][25][26][27] However, certain procedural limitations associated with stent placement, such as the need for meticulous vessel preparation and careful stent diameter selection, continue to exist. Moreover, stents are associated with the risk of fracture and can increase the neointimal hyperplastic response and result in restenosis and the need for additional interventions in the future.…”

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

“…A recent midterm report on the use of an interwoven nitinol stent (Supera) claims high patency rates in the treatment of long lesions. 41) Literature has emerged regarding the role of primary atherectomy for femoropopliteal disease. Despite the different types of atherectomy devices (laser, directional, orbital), [42][43][44][45][46][47] there remain concerns regarding the risk of distal embolic debris and restenosis with this strategy.…”